Abstract
Re-investigation of the methanolic extract of the sponge Diacarnus megaspinorhabdosa afforded one new norsesterpene cyclic peroxide megaspinoxide A (2), together with two known compounds sigmosceptrellin B (1) and nebularine (3). The structures of the isolated compounds were established on the basis of one and two dimensional NMR spectroscopic studies (1H, 13C, DEPT, COSY, HMQC, HMBC, and ROESY) as well as, mass spectral analysis. The isolated compounds were evaluated for their cytotoxic and antimicrobial activities.
Keywords: Diacarnus megaspinorhabdosa, norsesterpene, megaspinoxide A, sigmosceptrellin B, nebularine, cytotoxic, antimicrobial.
The Natural Products Journal
Title:Megaspinoxide A: New Norterpene Cyclic Peroxide from the Sponge Diacarnus megaspinorhabdosa
Volume: 4 Issue: 1
Author(s): Sabrin R.M. Ibrahim, Rwaida A. Al Haidari and Gamal A. Mohamed
Affiliation:
Keywords: Diacarnus megaspinorhabdosa, norsesterpene, megaspinoxide A, sigmosceptrellin B, nebularine, cytotoxic, antimicrobial.
Abstract: Re-investigation of the methanolic extract of the sponge Diacarnus megaspinorhabdosa afforded one new norsesterpene cyclic peroxide megaspinoxide A (2), together with two known compounds sigmosceptrellin B (1) and nebularine (3). The structures of the isolated compounds were established on the basis of one and two dimensional NMR spectroscopic studies (1H, 13C, DEPT, COSY, HMQC, HMBC, and ROESY) as well as, mass spectral analysis. The isolated compounds were evaluated for their cytotoxic and antimicrobial activities.
Export Options
About this article
Cite this article as:
R.M. Ibrahim Sabrin, A. Al Haidari Rwaida and A. Mohamed Gamal, Megaspinoxide A: New Norterpene Cyclic Peroxide from the Sponge Diacarnus megaspinorhabdosa, The Natural Products Journal 2014; 4(1) . https://dx.doi.org/10.2174/221031550401140715145414
DOI https://dx.doi.org/10.2174/221031550401140715145414 |
Print ISSN 2210-3155 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3163 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy
Current Clinical Pharmacology Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Current Enzyme Inhibition Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Imatinib and Its Successors – How Modern Chemistry has Changed Drug Development
Current Pharmaceutical Design State of the Art and Perspectives in Food Allergy (Part I): Diagnosis
Current Pharmaceutical Design New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design Site-directed Mutagenesis Study of the Ile140 in Conserved Hydrophobic Core of Bcl-xL
Protein & Peptide Letters The Clinical and Immunological Features of Patients with Primary Antibody Deficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets Current and Emerging Therapies in Primary Myelofibrosis
Cardiovascular & Hematological Disorders-Drug Targets New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations
Current Topics in Medicinal Chemistry Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine AKT: A Potential Target for Thyroid Cancer Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders A Comprehensive Proteomic Study of the Skin Secretions of the Frog Lithobates spectabilis
Protein & Peptide Letters The Antitumoral Mode of Action of Imiquimod and Other Imidazoquinolines
Current Medicinal Chemistry Thiopurine Biotransformation and Pharmacological Effects: Contribution of Oxidative Stress
Current Drug Metabolism miR-202 Mediates Metabolic Shift in Lung Cancer Cells via Targeting HK2
Current Signal Transduction Therapy